Effect of omega-3 fatty acid supplementation on the arachidonic acid

eicosapentaenoic acid ratio

Tammy Burns, Stephanie R. Maciejewski, William R. Hamilton, Margaret Zheng, Aryan N. Mooss, Daniel E. Hilleman

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Study Objectives. To determine the baseline arachidonic acid:eicosapentaenoic acid (AA:EPA) ratio in patients with coronary artery disease and healthy subjects, and whether supplementation of omega-3 fatty acids, administered as fish oil capsules, affects this ratio. Design. Prospective, open-label trial. Setting. University-affiliated cardiology clinic. Subjects. Thirty patients with stable coronary artery disease (CAD) and 30 healthy subjects. Intervention. All participants received omega-3 fatty acids 1.5 g/day for 4 weeks, followed by 3 g/day for an additional 4 weeks. Measurements and Main Results. For each participant, a lipid profile was determined at baseline and after 4 weeks of treatment with each dose. Other laboratory results analyzed were serum AA:EPA ratios, high-sensitivity C-reactive protein (hs-CRP) levels, and blood glucose levels. Mean ± SD baseline AA:EPA ratios were 39.6 ± 19.0 in healthy subjects and 23.7 ± 12.5 in patients with CAD. These ratios decreased significantly in both groups after treatment with 1.5 g/day of omega-3 fatty acids: 9.0 ± 4.2 in healthy subjects and 10.3 ± 8.8 in patients with CAD. After treatment with 3 g/day, the ratios were further reduced: 5.1 ± 3.2 in healthy subjects and 4.9 ± 2.6 in patients with CAD. Supplementation with omega-3 fatty acids did not significantly affect hs-CRP, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, or blood glucose levels. Triglyceride levels were not reduced in patients with CAD but were significantly decreased in healthy subjects (by 20% decrease with omega-3 fatty acids 1.5 g/day and by 32% decrease with 3 g/day). Conclusion. Treatment with omega-3 fatty acids significantly reduced AA:EPA ratios in both healthy subjects and in patients with stable CAD. The treatment had no effect on hs-CRP levels in either group, and it reduced triglyceride levels in healthy subjects but not in patients with CAD.

Original languageEnglish
Pages (from-to)633-638
Number of pages6
JournalPharmacotherapy
Volume27
Issue number5
DOIs
StatePublished - May 2007

Fingerprint

Eicosapentaenoic Acid
Omega-3 Fatty Acids
Arachidonic Acid
Coronary Artery Disease
Healthy Volunteers
C-Reactive Protein
Blood Glucose
Triglycerides
Therapeutics
Fish Oils
Cardiology
LDL Cholesterol
HDL Cholesterol
Capsules
Lipids
Serum

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Effect of omega-3 fatty acid supplementation on the arachidonic acid : eicosapentaenoic acid ratio. / Burns, Tammy; Maciejewski, Stephanie R.; Hamilton, William R.; Zheng, Margaret; Mooss, Aryan N.; Hilleman, Daniel E.

In: Pharmacotherapy, Vol. 27, No. 5, 05.2007, p. 633-638.

Research output: Contribution to journalArticle

Burns, Tammy ; Maciejewski, Stephanie R. ; Hamilton, William R. ; Zheng, Margaret ; Mooss, Aryan N. ; Hilleman, Daniel E. / Effect of omega-3 fatty acid supplementation on the arachidonic acid : eicosapentaenoic acid ratio. In: Pharmacotherapy. 2007 ; Vol. 27, No. 5. pp. 633-638.
@article{780df30c20a4457aae9f1b8891fe7206,
title = "Effect of omega-3 fatty acid supplementation on the arachidonic acid: eicosapentaenoic acid ratio",
abstract = "Study Objectives. To determine the baseline arachidonic acid:eicosapentaenoic acid (AA:EPA) ratio in patients with coronary artery disease and healthy subjects, and whether supplementation of omega-3 fatty acids, administered as fish oil capsules, affects this ratio. Design. Prospective, open-label trial. Setting. University-affiliated cardiology clinic. Subjects. Thirty patients with stable coronary artery disease (CAD) and 30 healthy subjects. Intervention. All participants received omega-3 fatty acids 1.5 g/day for 4 weeks, followed by 3 g/day for an additional 4 weeks. Measurements and Main Results. For each participant, a lipid profile was determined at baseline and after 4 weeks of treatment with each dose. Other laboratory results analyzed were serum AA:EPA ratios, high-sensitivity C-reactive protein (hs-CRP) levels, and blood glucose levels. Mean ± SD baseline AA:EPA ratios were 39.6 ± 19.0 in healthy subjects and 23.7 ± 12.5 in patients with CAD. These ratios decreased significantly in both groups after treatment with 1.5 g/day of omega-3 fatty acids: 9.0 ± 4.2 in healthy subjects and 10.3 ± 8.8 in patients with CAD. After treatment with 3 g/day, the ratios were further reduced: 5.1 ± 3.2 in healthy subjects and 4.9 ± 2.6 in patients with CAD. Supplementation with omega-3 fatty acids did not significantly affect hs-CRP, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, or blood glucose levels. Triglyceride levels were not reduced in patients with CAD but were significantly decreased in healthy subjects (by 20{\%} decrease with omega-3 fatty acids 1.5 g/day and by 32{\%} decrease with 3 g/day). Conclusion. Treatment with omega-3 fatty acids significantly reduced AA:EPA ratios in both healthy subjects and in patients with stable CAD. The treatment had no effect on hs-CRP levels in either group, and it reduced triglyceride levels in healthy subjects but not in patients with CAD.",
author = "Tammy Burns and Maciejewski, {Stephanie R.} and Hamilton, {William R.} and Margaret Zheng and Mooss, {Aryan N.} and Hilleman, {Daniel E.}",
year = "2007",
month = "5",
doi = "10.1592/phco.27.5.633",
language = "English",
volume = "27",
pages = "633--638",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Effect of omega-3 fatty acid supplementation on the arachidonic acid

T2 - eicosapentaenoic acid ratio

AU - Burns, Tammy

AU - Maciejewski, Stephanie R.

AU - Hamilton, William R.

AU - Zheng, Margaret

AU - Mooss, Aryan N.

AU - Hilleman, Daniel E.

PY - 2007/5

Y1 - 2007/5

N2 - Study Objectives. To determine the baseline arachidonic acid:eicosapentaenoic acid (AA:EPA) ratio in patients with coronary artery disease and healthy subjects, and whether supplementation of omega-3 fatty acids, administered as fish oil capsules, affects this ratio. Design. Prospective, open-label trial. Setting. University-affiliated cardiology clinic. Subjects. Thirty patients with stable coronary artery disease (CAD) and 30 healthy subjects. Intervention. All participants received omega-3 fatty acids 1.5 g/day for 4 weeks, followed by 3 g/day for an additional 4 weeks. Measurements and Main Results. For each participant, a lipid profile was determined at baseline and after 4 weeks of treatment with each dose. Other laboratory results analyzed were serum AA:EPA ratios, high-sensitivity C-reactive protein (hs-CRP) levels, and blood glucose levels. Mean ± SD baseline AA:EPA ratios were 39.6 ± 19.0 in healthy subjects and 23.7 ± 12.5 in patients with CAD. These ratios decreased significantly in both groups after treatment with 1.5 g/day of omega-3 fatty acids: 9.0 ± 4.2 in healthy subjects and 10.3 ± 8.8 in patients with CAD. After treatment with 3 g/day, the ratios were further reduced: 5.1 ± 3.2 in healthy subjects and 4.9 ± 2.6 in patients with CAD. Supplementation with omega-3 fatty acids did not significantly affect hs-CRP, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, or blood glucose levels. Triglyceride levels were not reduced in patients with CAD but were significantly decreased in healthy subjects (by 20% decrease with omega-3 fatty acids 1.5 g/day and by 32% decrease with 3 g/day). Conclusion. Treatment with omega-3 fatty acids significantly reduced AA:EPA ratios in both healthy subjects and in patients with stable CAD. The treatment had no effect on hs-CRP levels in either group, and it reduced triglyceride levels in healthy subjects but not in patients with CAD.

AB - Study Objectives. To determine the baseline arachidonic acid:eicosapentaenoic acid (AA:EPA) ratio in patients with coronary artery disease and healthy subjects, and whether supplementation of omega-3 fatty acids, administered as fish oil capsules, affects this ratio. Design. Prospective, open-label trial. Setting. University-affiliated cardiology clinic. Subjects. Thirty patients with stable coronary artery disease (CAD) and 30 healthy subjects. Intervention. All participants received omega-3 fatty acids 1.5 g/day for 4 weeks, followed by 3 g/day for an additional 4 weeks. Measurements and Main Results. For each participant, a lipid profile was determined at baseline and after 4 weeks of treatment with each dose. Other laboratory results analyzed were serum AA:EPA ratios, high-sensitivity C-reactive protein (hs-CRP) levels, and blood glucose levels. Mean ± SD baseline AA:EPA ratios were 39.6 ± 19.0 in healthy subjects and 23.7 ± 12.5 in patients with CAD. These ratios decreased significantly in both groups after treatment with 1.5 g/day of omega-3 fatty acids: 9.0 ± 4.2 in healthy subjects and 10.3 ± 8.8 in patients with CAD. After treatment with 3 g/day, the ratios were further reduced: 5.1 ± 3.2 in healthy subjects and 4.9 ± 2.6 in patients with CAD. Supplementation with omega-3 fatty acids did not significantly affect hs-CRP, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, or blood glucose levels. Triglyceride levels were not reduced in patients with CAD but were significantly decreased in healthy subjects (by 20% decrease with omega-3 fatty acids 1.5 g/day and by 32% decrease with 3 g/day). Conclusion. Treatment with omega-3 fatty acids significantly reduced AA:EPA ratios in both healthy subjects and in patients with stable CAD. The treatment had no effect on hs-CRP levels in either group, and it reduced triglyceride levels in healthy subjects but not in patients with CAD.

UR - http://www.scopus.com/inward/record.url?scp=34247850808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247850808&partnerID=8YFLogxK

U2 - 10.1592/phco.27.5.633

DO - 10.1592/phco.27.5.633

M3 - Article

VL - 27

SP - 633

EP - 638

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 5

ER -